Ryan Specialty Group (RYAN) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
29 Oct, 2026Business model and scale
Ranked #2 in wholesale brokerage and #1 in delegated underwriting authority by 2025 premium volume; placed ~$32bn and ~$15bn of premiums, respectively.
2025 revenue was $3.1bn and adjusted EBITDAC was ~$1.0bn; 35k+ retail brokers and 350+ carrier trading partners support distribution at scale.
Wholesale brokerage connects brokers with specialty capacity for complex risks; delegated underwriting designs, binds, administers, and services risks for carrier partners.
Specialty distribution mix was 52% wholesale and 48% delegated underwriting authority, based on 9/30/26 LTM net commissions and fees.
Differentiated platform and talent
Combined wholesale and delegated underwriting platforms provide a broad view of specialty risk, proprietary data, carrier relationships, and capacity to develop bespoke solutions.
Wholesale expertise spans property, casualty, and professional lines; 82% of written premium was non-admitted as of 12/31/25.
Delegated underwriting spans 300+ products across 160+ facilities; ~2/3 of premium is syndicated across multiple carriers, with underwriting profitability driving compensation.
Producer and underwriter retention averaged 97% and 96%, respectively, over 2021-2025; 71% of producers grew their book in 2025.
2025 producer hiring class was the second largest to date; new hires typically cover costs by year two and reach target margins by year three.
Market opportunity and growth strategy
E&S share of North American commercial P&C premiums rose from 7% in 2000 to 27% in 2025; 2000-2025 E&S CAGR was 10.6%, versus 3.7% for admitted premiums.
MGA market grew at an 11% CAGR over the prior 10 years, supported by demand for specialized underwriting, efficient carrier access, and innovative products.
Addressable markets include ~$140bn in E&S wholesale, ~$60bn in specialty admitted, ~$125bn in MGA/MGU, ~$110bn in reinsurance, ~$135bn in alternative capital, and ~$40bn in medical stop loss.
Deployed 63 M&A deals since founding; acquired revenue totaled ~$530mn. Strategy targets complementary, accretive businesses with cultural fit and supports integration through shared capabilities and infrastructure.
Empower is intended to streamline broking and underwriting, optimize the platform, and accelerate data and technology investment; stated goal is modest margin expansion in most years.
Latest events from Ryan Specialty Group
- Revenue and adjusted EPS grew despite pricing pressure; FY margin guidance improved to ~50 bps down.RYAN
Q3 2026 - Q2 2026 revenue up 7.2% to $916.6M, strong margins, and $284.5M returned to shareholders.RYAN
Q2 2026 - Scale, innovation, and disciplined growth drive resilience and leadership in specialty insurance.RYAN
46th Annual William Blair Growth Stock Conference - Revenue up 15.2% to $795.2M, organic growth 11.8%, net income $40.6M, margin pressure ahead.RYAN
Q1 2026 - Record revenue, expanded shareholder rights, and a focus on performance-based leadership mark 2025.RYAN
Proxy Filing - Shareholders will vote on director elections, auditor ratification, and executive pay approval.RYAN
Proxy Filing - Revenue up 18.8% and net income up 40.8%, with margin and guidance both raised.RYAN
Q2 2024 - Q3 revenue up 20.5%, net income up 82.4%, and adjusted EBITDAC up 29.4% year-over-year.RYAN
Q3 2024 - Revenue up 25% and adjusted EBITDAC up 27.5%, but net income impacted by non-cash tax expense.RYAN
Q1 2025